【摘要】 目的 分析重组人血管内皮抑制素注射液(恩度)联合吉西他滨和顺铂(GP)方案治疗Ⅲb～Ⅳ期食管癌患者的临床疗效及不良反应。方法 回顾性分析2019年4月至2021年4月郑州大学第一附属医院接受GP方案治疗的97例Ⅲb～Ⅳ期食管癌患者的临床病理资料，根据是否加用恩度分为观察组和对照组，采用恩度联合GP方案治疗的56例患者为观察组，采用单一GP方案治疗的41例患者为对照组，比较2组患者总有效率、血清血管内皮生长因子(VEGF)水平、不良反应发生率及生存情况。结果 观察组有效率高于对照组(χ~2=5.820,P=0.016)。观察组和对照组治疗后VEGF水平均低于同组治疗前(t=16.541,P<0.001;t=11.571,P<0.001),且观察组治疗后血清VEGF水平低于对照组(t=11.964,P<0.001)。2组肝功能异常、恶心呕吐、便秘、骨髓抑制、神经感觉障碍发生率比较差异均无统计学意义(χ~2=0.243,P=0.622;χ~2=0.077,P=0.781;χ~2=0.000,P=1.000;χ~2=0.037,P=0.847;χ~2=0.890,P=0.345)。2组患者3、6个月生存率比较差异均无统计学意义(χ~2=0.741,P=0.389;χ~2=1.850,P=0.174),而12个月生存率比较差异有统计学意义(χ~2=5.695,P=0.017)。结论 恩度联合GP方案可显著提高晚期食管癌患者临床疗效，抑制食管癌血管生成，延长生存期，具有很好的临床应用前景。更多还原

【Abstract】 Objective To analyze the clinical efficacy and side effects of recombinant human endostatin injection(Endu) combined with gemcitabine plus cisplatin(GP) regimen in the treatment of stage Ⅲb-Ⅳ esophageal cancer. Methods The clinicopathological data of 97 patients with stage Ⅲb-Ⅳ esophageal cancer treated by GP regimen from the First Affiliated Hospital of Zhengzhou University were analyzed retrospectively. They were divided into the observation group and the control group according to whether treated with Endu. Fifty-six patients in the observation group were treated with Endu combined with GP regimen, and 41 patients in the control group were treated with single GP regimen. The total effective rate, serum vascular endothelial growth factor(VEGF) level, incidence of adverse reactions and survival rate of the two groups were statistically compared. Results The effective rate of the observation group was higher than that of the control group(χ~2=5.820,P=0.016). The serum VEGF levels after treatment were lower than those before treatment in the observation group and the control group(t=16.541, P<0.001; t=11.571, P<0.001), and the serum VEGF levels in the observation group after treatment were lower than those in the control group(t=11.964, P<0.001). There was no statistically significant difference in the incidences of liver dysfunction, nausea, vomiting, constipation, bone marrow suppression and neurosensory disorders between the two groups(χ~2=0.243,P=0.622;χ~2=0.077,P=0.781;χ~2=0.000,P=1.000;χ~2=0.037,P=0.847;χ~2=0.890,P=0.345). There was no statistically significant difference in the 3-month and 6-month survival rates between the two groups(χ~2=0.741,P=0.389;χ~2=1.850,P=0.174), but there was a significant difference in the 12-month survival rate(χ~2=5.695,P=0.017). Conclusion Endu combined with GP can significantly improve the clinical efficacy of patients with advanced esophageal cancer, inhibit the angiogenesis of esophageal cancer, and prolong the survival time of patients. It has a good clinical application prospect.更多还原